LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651
Argiris, A., Harrington, K., Tahara, M., Ferris, R.L., Gillison, M., Fayette, J., Daste, A., Koralewski, P., Mesia Nin, R., Saba, N.F., Mak, M., Álvarez Avitia, M.A., Guminski, A., Müller-Richter, U., Kiyota, N., Roberts, M., Khan, T.A., Miller-Moslin, K., Wei, L., Robert Haddad, R.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article